7498 Results (Page 15 of 300)
Pharmaceuticals Markets Research Reports
Indonesia Clinical Nutrition for Cancer Care Market Analysis
The Indonesia Clinical Nutrition for Cancer Care Market was valued at $33.78 Mn in 2023 and is predicted to grow at a CAGR of 5.04% from 2023 to 2030, to $47.76 Mn by 2030. The key drivers of the market include the increasing prevalence of cancer, increasing risk of malnutrition in oncology patients, and advancements in nutritional products. The prominent players of the Indonesia Clinical Nutrition for Cancer Care Market are Reckitt Benckiser, Nestlé Health Science, Abbott Nutrition, B. Braun Melsungen AG, and Fresenius Kabi, among others.
Germany Exosome Research Market Analysis
The Germany Exosome Research Market was valued at $6.2 Mn in 2023 and is projected to grow at a CAGR of 14.2% from 2023 to 2023, to $15.7 Mn by 2030. The key drivers of this industry are increasing prevalence and incidences of cancer and various auto-immune diseases, rising healthcare expenditure for better health services, growing R&D activities associated with exosome research, technological advancements in exosome isolation and analytical procedures, and increasing advanced applications of exosomes. The industry is primarily dominated by players such as Thermo Fisher Scientific, NanoSomix, NX Pharmagen, Malvern Instruments, Capricor Therapeutic among others.
China Clinical Nutrition for Cancer Care Market Analysis
The China Clinical Nutrition for Cancer Care Market was valued at $452.6 Mn in 2023 and is predicted to grow at a CAGR of 6.54% from 2023 to 2030, to $705.2 Mn by 2030. The key drivers of the market include the increasing prevalence of cancer, increasing risk of malnutrition in oncology patients, and advancements in nutritional products. The prominent players of the China Clinical Nutrition for Cancer Care Market are MediFood, Nestlé Health Science, Abbott Nutrition, B. Braun Melsungen AG, and Fresenius Kabi, among others.
Mexico Clinical Nutrition for Cancer Care Market Analysis
The Mexico Clinical Nutrition for Cancer Care Market was valued at $84.5 Mn in 2023 and is predicted to grow at a CAGR of 5.29% from 2023 to 2030, to $121.2 Mn by 2030. The key drivers of the market include the increasing prevalence of cancer, improved healthcare infrastructure, and rising disposable incomes. The prominent players of the Mexico Clinical Nutrition for Cancer Care Market are Nestlé Health Science, Abbott Nutrition, B. Braun Melsungen AG, and Fresenius Kabi, among others.
UK Clinical Nutrition for Cancer Care Market Analysis
The UK Clinical Nutrition for Cancer Care Market was valued at $146.4 Mn in 2023 and is predicted to grow at a CAGR of 3.04% from 2023 to 2030, to $180.5 Mn by 2030. The key drivers of the market include the increasing prevalence of cancer, increased awareness and education, and increasing healthcare expenditure. The prominent players of the UK Clinical Nutrition for Cancer Care Market are Baxter, Nestlé Health Science, Abbott Nutrition, Nutricia, and Fresenius Kabi, among others.
Spain Clinical Nutrition for Cancer Care Market Analysis
The Spain Clinical Nutrition for Cancer Care Market was valued at $108.7 Mn in 2023 and is predicted to grow at a CAGR of 4.04% from 2023 to 2030, to $143.4 Mn by 2030. The key drivers of the market include the increasing prevalence of cancer, increased awareness and education, and increasing healthcare expenditure. The prominent players of the Spain Clinical Nutrition for Cancer Care Market are Fresenius Kabi España, Baxter España, and Clinical Nutrition SAU, among others.
Germany Clinical Nutrition for Cancer Care Market Analysis
The Germany Clinical Nutrition for Cancer Care Market was valued at $206.1 Mn in 2023 and is predicted to grow at a CAGR of 3.24% from 2023 to 2030, to $257.6 Mn by 2030. The key drivers of the market include the increasing prevalence of cancer, increased awareness and education, and increasing healthcare expenditure. The prominent players of the Germany Clinical Nutrition for Cancer Care Market are Fresenius Kabi, Baxter Deutschland GmbH, Dr. Franz Schneider GmbH & Co. KG, Nutricia GmbH, and B. Braun Melsungen AG, among others.
France Clinical Nutrition for Cancer Care Market Analysis
The France Clinical Nutrition for Cancer Care Market was valued at $154.8 Mn in 2023 and is predicted to grow at a CAGR of 4.04% from 2023 to 2030, to $204.3 Mn by 2030. The key drivers of the market include the increasing prevalence of cancer, increased awareness and education, and increasing healthcare expenditure. The prominent players of the France Clinical Nutrition for Cancer Care Market are Danone Nutricia, Laboratories Lactalis Nutrition Santé (LNS), Nestlé Health Science, Abbott Nutrition, B. Braun Melsungen AG, Pfizer, and Fresenius Kabi, among others.
Mexico Clinical Nutrition for Diabetes Care Market Analysis
The Mexico Clinical Nutrition for Diabetes Care Market was valued at $32.25 Mn in 2023 and is predicted to grow at a CAGR of 5.03% from 2023 to 2030, to $45.47 Mn by 2030. The key drivers of this industry include increasing the prevalence of diabetes, advancements in nutritional science, and initiatives for diabetes management. The key players in the industry are Nestle Health Science, Sanofi, Pfizer Inc., and Abbott Nutrition among others.
Brazil Clinical Nutrition for Cancer Care Market Analysis
The Brazil Clinical Nutrition for Cancer Care Market was valued at $140.8 Mn in 2023 and is predicted to grow at a CAGR of 6.04% from 2023 to 2030, to $212.2 Mn by 2030. The key drivers of the market include the increasing prevalence of cancer, improved healthcare infrastructure, and rising disposable incomes. The prominent players of the Brazil Clinical Nutrition for Cancer Care Market are Nestlé Health Science, Abbott Nutrition, B. Braun Melsungen AG, and Fresenius Kabi, among others.
UAE Clinical Nutrition for Cancer Care Market Analysis
The UAE Clinical Nutrition for Cancer Care Market was valued at $28.1 Mn in 2023 and is predicted to grow at a CAGR of 6.04% from 2023 to 2030, to $42.4 Mn by 2030. The key drivers of the market include the increasing prevalence of cancer, improved healthcare infrastructure, and rising disposable incomes. The prominent players of the UAE Clinical Nutrition for Cancer Care Market are Nestlé Health Science, Abbott Nutrition, B. Braun Melsungen AG, Pfizer, and Fresenius Kabi, among others.
Saudi Arabia Clinical Nutrition for Cancer Care Market Analysis
The Saudi Arabia Clinical Nutrition for Cancer Care Market was valued at $95.7 Mn in 2023 and is predicted to grow at a CAGR of 6.54% from 2023 to 2030, to $149.1 Mn by 2030. The key drivers of the market include the increasing prevalence of cancer, improved healthcare infrastructure, and rising disposable incomes. The prominent players of the Saudi Arabia Clinical Nutrition for Cancer Care Market are Almarai, Nestlé Health Science, Abbott Nutrition, B. Braun Melsungen AG, and Fresenius Kabi, among others.
US Clinical Nutrition for Cancer Care Market Analysis
The US Clinical Nutrition for Cancer Care Market was valued at $2,364.6 Mn in 2023 and is predicted to grow at a CAGR of 3.04 % from 2023 to 2030, to $2,916.07 Mn by 2030. The key drivers of the market include the increasing prevalence of cancer, increased awareness and education, and increasing healthcare expenditure. The prominent players of the US Clinical Nutrition for Cancer Care Market are Nestlé Health Science, Abbott Nutrition, B. Braun Melsungen AG, Pfizer, and Fresenius Kabi, among others.
Canada Clinical Nutrition for Cancer Care Market Analysis
The Canada Clinical Nutrition for Cancer Care Market was valued at $450.4 Mn in 2023 and is predicted to grow at a CAGR of 5.04% from 2023 to 2030, to $635.5 Mn by 2030. The key drivers of the market include the increasing prevalence of cancer, increased awareness and education, and increasing healthcare expenditure. The prominent players of the Canada Clinical Nutrition for Cancer Care Market are Nestlé Health Science, Abbott Nutrition, B. Braun Melsungen AG, Pfizer, and Fresenius Kabi, among others.
South Africa Gram-Negative Infection Therapeutics Market Analysis
The South Africa Gram-Negative Infection Therapeutics Market was valued at $96.7 Mn in 2023 and is predicted to grow at a CAGR of 7.13% from 2023 to 2030 to $156.6 Mn by 2030. Factors driving this growth encompass the high prevalence of multidrug-resistant (MDR) infections, rising awareness, and the expanding population with aging demographics. Leading companies in this market comprise Sanofi-Aventis, Eli Lilly and Company, and other notable entities.
Kenya Gram-Negative Infection Therapeutics Market Analysis
The Kenya Gram-Negative Infection Therapeutics Market was valued at $10.4 Mn in 2023 and is predicted to grow at a CAGR of 7% from 2023 to 2030 to $16.7 Mn by 2030. This growth is driven by rising antibiotic resistance, a high prevalence of multidrug-resistant (MDR) infections, and increasing awareness. Leading companies in this market include Baxter and AbbVie Inc., among others.
Egypt Gram-Negative Infection Therapeutics Market Analysis
The Egypt Gram-Negative Infection Therapeutics Market was valued at $41.6 Mn in 2023 and is predicted to grow at a CAGR of 7.4% from 2023 to 2030 to $68.7 Mn by 2030. The primary drivers of this market expansion encompass the growing incidence of gram-negative bacterial infections, the challenge of antimicrobial resistance, and collaborative efforts through partnerships. Major players in this sector in Egypt include Janssen Pharmaceuticals, Inc. and Bristol-Myers Squibb Company, among others.
Vietnam Gram-Negative Infection Therapeutics Market Analysis
The Vietnam Gram-Negative Infection Therapeutics Market was valued at $74.4 Mn in 2023 and is predicted to grow at a CAGR of 6.13% from 2023 to 2030 to $112.8 Mn by 2030. This growth is fuelled by factors such as the increasing prevalence of antibiotic resistance, elevated rates of colonization with resistant strains, and rising mortality rates. Key players in this market include Merck, Takeda, Novartis, and other notable companies.
Singapore Gram-Negative Infection Therapeutics Market Analysis
The Singapore Gram-Negative Infection Therapeutics Market was valued at $17.8 Mn in 2023 and is predicted to grow at a CAGR of 6.5% from 2023 to 2030 to $27.7 Mn by 2030. Factors driving this expansion include increasing prevalence, rising demand for effective treatments, and an aging population. Major companies in this market include Novartis, Merck, Roche, and others.
Philippines Gram-Negative Infection Therapeutics Market Analysis
The Philippines Gram-Negative Infection Therapeutics Market was valued at $32.7 Mn in 2023 and is predicted to grow at a CAGR of 6.4% from 2023 to 2030 to $50.5 Mn by 2030. Factors fuelling this expansion include rising prevalence, growing awareness of antibiotic resistance, and government initiatives. Key players in this market include AbbVie Inc., Bayer AG, and other significant firms.
Malaysia Gram-Negative Infection Therapeutics Market Analysis
The Malaysia Gram-Negative Infection Therapeutics Market was valued at $23.9 Mn in 2023 and is predicted to grow at a CAGR of 6.1% from 2023 to 2030 to $36.2 Mn by 2030. Key drivers of this growth include increasing antimicrobial resistance (AMR), an aging population, and government initiatives. Major companies in this market include Sumitomo, Baxter, and other prominent firms.
Japan Gram-Negative Infection Therapeutics Market Analysis
The Japan Gram-Negative Infection Therapeutics Market was valued at $924.6 Mn in 2023 and is predicted to grow at a CAGR of 6.4% from 2023 to 2030 to $1427.4 Mn by 2030. The primary factors fueling this market growth include the increasing challenge of antimicrobial resistance (AMR), the aging demographics, and government efforts. Major players in Japan's market include Eli Lilly and Company and Bayer AG, among others.
Indonesia Gram-Negative Infection Therapeutics Market Analysis
The Indonesia Gram-Negative Infection Therapeutics Market was valued at $89.2 Mn in 2023 and is predicted to grow at a CAGR of 5.9% from 2023 to 2030 to $133.3 Mn by 2030. The main factors driving this market expansion include the rising prevalence of hospital-acquired infections (HAIs), increased demand due to the widespread overuse and misuse of antibiotics, and a fragmented healthcare system. Leading companies in this market in Indonesia include Kalbe Farma and Bio Farma, among others.
China Gram-Negative Infection Therapeutics Market Analysis
The China Gram-Negative Infection Therapeutics Market was valued at $1195.84 Mn in 2023 and is predicted to grow at a CAGR of 7.4% from 2023 to 2030 to $1970.9 Mn by 2030. The key drivers of this market expansion include public health initiatives, the rising incidence of gram-negative infections, and the growing demand for effective treatments. The leading companies operating in this market in China include Merck & Co., Inc. and AstraZeneca, among others.
UK Gram-Negative Infection Therapeutics Market Analysis
The UK Gram-Negative Infection Therapeutics Market was valued at $386.8 Mn in 2023 and is predicted to grow at a CAGR of 3.9% from 2023 to 2030 to $505.5 Mn by 2030. Public health initiatives, rising incidence of infections, and a growing demand for effective treatments drive this market expansion. Leading companies in this market include GlaxoSmithKline plc (GSK), Pfizer Inc., Novartis, Takeda, and Baxter, among others.